<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1104210674
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Lipofirate
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FENOFIBRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        145
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        37.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary Hypercholesterolemia or Mixed Dyslipidemia</p><p>Fenofibrate Tablets is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe Hypertriglyceridemia</p><p>Fenofibrate Tablets is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. &gt; 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been</p><p>adequately studied.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Important Limitations of Use Fenofibrate at a dose equivalent to 145 mg of Fenofibrate Tablets was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Patients should be placed on an appropriate lipid-lowering diet before receiving Fenofibrate Tablets, and should continue this diet during treatment with Fenofibrate Tablets. Fenofibrate Tablets can be given without regard to meals.</p><p>The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia.</p><p>Lipid levels should be monitored periodically and consideration should be given to reducing the dosage of Fenofibrate Tablets if lipid levels fall significantly below the targeted range.</p><p>Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of 145 mg once daily</p><p>Warnings and Precautions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Mortality and Coronary Heart Disease Morbidity</strong></p><p>The effect of Fenofibrate Tablets on coronary heart disease morbidity and mortality and non- cardiovascular mortality has not been established.</p><p>The Action to Control Cardiovascular Risk in Diabetes Lipid (ACCORD Lipid) trial was a randomized placebo-controlled study of 5518 patients with type 2 diabetes mellitus on background statin therapy treated with fenofibrate. The mean duration of follow-up was 4.7 years. Fenofibrate plus statin combination therapy showed a non-significant 8% relative risk reduction in the primary outcome of major adverse cardiovascular events (MACE), a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular disease death (hazard ratio [HR] 0.92, 95% CI 0.79- 1.08) (p=0.32) as compared to statin monotherapy. In a gender subgroup analysis, the hazard ratio</p><p>&nbsp;</p><p>for MACE in men receiving combination therapy versus statin monotherapy was 0.82 (95% CI 0.69-0.99), and the hazard ratio for MACE in women receiving combination therapy versus statin monotherapy was 1.38 (95% CI 0.98-1.94)</p><p>(interaction p=0.01). The clinical significance of this subgroup finding is unclear. The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study was a 5-year randomized, placebo- controlled study of 9795 patients with type 2 diabetes mellitus treated with fenofibrate. Fenofibrate demonstrated a non-significant 11% relative reduction in the primary outcome of coronary heart disease events (hazard ratio [HR] 0.89, 95% CI 0.75-1.05, p=0.16) and a significant 11% reduction in the secondary outcome of total cardiovascular disease events (HR 0.89 [0.80-0.99], p=0.04). There was a non-significant 11% (HR 1.11 [0.95, 1.29], p=0.18) and 19% (HR 1.19 [0.90, 1.57], p=0.22) increase in total and coronary heart disease mortality, respectively, with fenofibrate as compared to placebo.</p><p>Because of chemical, pharmacological, and clinical similarities between Fenofibrate Tablets (fenofibrate tablets), clofibrate, and gemfibrozil, the adverse findings in 4 large randomized, placebo controlled clinical studies with these other fibrate drugs may also apply to Fenofibrate Tablets.</p><p>In the Coronary Drug Project, a large study of post myocardial infarction of patients treated for 5 years with clofibrate, there was no difference in mortality seen between the clofibrate group and the placebo group. There was however, a difference in the rate of cholelithiasis and cholecystitis requiring surgery between the two groups (3.0% vs. 1.8%). In a study conducted by the World Health Organization (WHO), 5000 subjects without known coronary artery disease were treated with placebo or clofibrate for 5 years and followed for an additional one year. There was a statistically significant, higher age &minus; adjusted all-cause mortality in the clofibrate group compared with the placebo group (5.70% vs. 3.96%, p = &lt; 0.01). Excess mortality was due to a 33% increase in non-cardiovascular causes, including malignancy, post-cholecystectomy complications, and pancreatitis. This appeared to confirm the higher risk of gallbladder disease seen in clofibrate- treated patients studied in the Coronary Drug Project. The Helsinki Heart Study was a large (n=4081) study of middle-aged men without a history of coronary artery disease. Subjects received either placebo or gemfibrozil for 5 years, with a 3.5 year open extension afterward. Total mortality was numerically higher in the gemfibrozil randomization group but did not achieve statistical significance (p = 0.19, 95% confidence interval for relative risk G:P = .91-1.64). Although cancer</p><p>&nbsp;</p><p>deaths trended higher in the gemfibrozil group (p = 0.11), cancers (excluding basal cell carcinoma) were diagnosed with equal frequency in both study groups. Due to the limited size of the study, the relative risk of death from any cause was not shown to be different than that seen in the 9 year follow-up data from World Health Organization study (RR=1.29).</p><p>A secondary prevention component of the Helsinki Heart Study enrolled middle-aged men excluded from the primary prevention study because of known or suspected coronary heart disease. Subjects received gemfibrozil or placebo for 5 years. Although cardiac deaths trended higher in the gemfibrozil group, this was not statistically significant (hazard ratio 2.2, 95% confidence interval: 0.94-5.05). The rate of gallbladder surgery was not statistically significant between study groups, but did trend higher in the gemfibrozil group, (1.9% vs. 0.3%, p = 0.07).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skeletal Muscle</p><p>Fibrates increase the risk for myopathy and have been associated with rhabdomyolysis. The risk for serious muscle toxicity appears to be increased in elderly patients and in patients with diabetes, renal insufficiency, or hypothyroidism.</p><p>Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevations of creatine phosphokinase (CPK) levels. Patients should be advised to report promptly unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. CPK levels should be assessed in patients reporting these symptoms, and Fenofibrate Tablets therapy should be discontinued if markedly elevated CPK&nbsp; levels occur or myopathy/myositis is suspected or diagnosed.</p><p>Data from observational studies indicate that the risk for rhabdomyolysis is increased when fibrates, in particular gemfibrozil, are co-administered with an HMG-CoA reductase inhibitor (statin). The combination should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates coadministered</p><p>With colchicine, and caution should be exercised when prescribing fenofibrate with colchicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver Function</p><p>Fenofibrate at doses equivalent to 96 mg to 145 mg Fenofibrate Tablets per day has been associated with increases in serum transaminases [AST (SGOT) or ALT (SGPT)]. In a pooled analysis of 10 placebo-controlled trials, increases to &gt; 3 times the upper limit of normal occurred in 5.3% of patients taking fenofibrate versus 1.1% of patients treated with placebo.</p><p>&nbsp;</p><p>When transaminase determinations were followed either after discontinuation of treatment or during continued treatment, a return to normal limits was usually observed. The incidence of increases in transaminases related to fenofibrate therapy appear to be dose related. In an 8-week dose-ranging study, the incidence of ALT or AST elevations to at least three times the upper limit of normal was 13% in patients receiving dosages equivalent to 96 mg to 145 mg Fenofibrate Tablets per day and was 0% in those receiving dosages equivalent to 48 mg or less Fenofibrate Tablets per day, or placebo. Hepatocellular, chronic active and cholestatic hepatitis associated with fenofibrate therapy have been reported after exposures of weeks to several years. In extremely rare cases, cirrhosis has been reported in association with chronic active hepatitis. Baseline and regular periodic monitoring of liver function, including serum ALT (SGPT) should be performed for the duration of therapy with Fenofibrate Tablets, and therapy discontinued if enzyme levels persist above three times the normal limit.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serum Creatinine</p><p>Elevations in serum creatinine have been reported in patients on fenofibrate. These elevations tend to return to baseline following discontinuation of fenofibrate. The clinical significance of these observations is unknown. Monitor renal function in patients with renal impairment taking Fenofibrate Tablets. Renal monitoring should also be considered for patients taking Fenofibrate Tablets at risk for renal insufficiency such as the elderly and patients with diabetes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cholelithiasis</p><p>Fenofibrate, like clofibrate and gemfibrozil, may increase cholesterol excretion into the bile, leading to Cholelithiasis. If Cholelithiasis is suspected, gallbladder studies are indicated. Fenofibrate Tablets therapy should be discontinued if gallstones are found.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coumarin Anticoagulants</p><p>Caution should be exercised when coumarin anticoagulants are given in conjunction with Fenofibrate Tablets because of the potentiation of coumarin-type anticoagulant effects in prolonging the Prothrombin Time/International Normalized Ratio (PT/INR). To prevent bleeding complications,</p><p>frequent monitoring of PT/INR and dose adjustment of the anticoagulant are recommended until PT/INR has stabilized.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pancreatitis</p><p>&nbsp;</p><p>Pancreatitis has been reported in patients taking fenofibrate, gemfibrozil, and clofibrate. This occurrence may represent a failure of efficacy in patients with severe hypertriglyceridemia, a direct drug effect, or a secondary phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hematologic Changes</p><p>Mild to moderate hemoglobin, haematocrit, and white blood cell decreases have been observed in patients following initiation of fenofibrate therapy. However, these levels stabilize during long term administration. Thrombocytopenia and agranulocytosis have been reported in individuals treated with fenofibrate. Periodic monitoring of red and white blood cell counts are recommended during the first 12 months of Fenofibrate Tablets administration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity Reactions</p><p>Acute Hypersensitivity</p><p>Anaphylaxis and angioedema have been reported postmarketing with fenofibrate. In some cases, reactions were life-threatening and required emergency treatment. If a patient develops signs or symptoms of an acute hypersensitivity reaction, advise them to seek immediate medical attention and discontinue fenofibrate.</p><p>Delayed Hypersensitivity</p><p>Severe cutaneous adverse drug reactions (SCAR), including Stevens-Johnson syndrome, toxic epidermal necrolysis, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported postmarketing, occurring days to weeks after initiation of fenofibrate. The cases of DRESS were associated with cutaneous reactions (such as rash or exfoliative dermatitis) and a combination of eosinophilia, fever, systemic organ involvement (renal, hepatic, or respiratory). Discontinue fenofibrate and treat patients appropriately if SCAR is suspected.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Venothromboembolic Disease</p><p>In the Field trial, pulmonary embolus (PE) and deep vein thrombosis (DVT) were observed at higher rates in the fenofibrate- than the placebo-treated group. Of 9,795 patients enrolled in FIELD, there were 4,900 in the placebo group and 4,895 in the fenofibrate group. For DVT, there were 48 events (1%) in the placebo group and 67 (1%) in the fenofibrate group (p = 0.074); and for PE, there were 32 (0.7%) events in the placebo group and 53 (1%) in the fenofibrate group (p</p><p>= 0.022). In the Coronary Drug Project, a higher proportion of the clofibrate group experienced</p><p>&nbsp;</p><p>definite or suspected fatal or nonfatal pulmonary embolism or thrombophlebitis than the placebo group (5.2% vs. 3.3% at five years; p &lt; 0.01).</p><p>Children and adolescents</p><p>Fenofibrate Tablets 48mg and 145mg should not be used in children. There are no data demonstrating efficacy or safety of fenofibrate Tablets in children.</p><p>Other medicines and Fenofibrate Tablets 48mg and 145mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coumarin Anticoagulants</p><p>Potentiation of coumarin-type anticoagulant effects has been observed with prolongation of the PT/INR. Caution should be exercised when coumarin anticoagulants are given in conjunction with Fenofibrate Tablets. The dosage of the anticoagulants should be reduced to maintain the PT/INR at the desired level to prevent bleeding complications. Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized [see Warnings and Precautions (5.6)].</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immunosuppressant&rsquo;s</p><p>Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including Fenofibrate Tablets, there is a risk that an interaction will lead to deterioration of renal function. The benefits and risks of using (fenofibrate tablets) with immunosuppressant&rsquo;s and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed and renal function monitored.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bile Acid Binding Resins</p><p>Since bile acid binding resins may bind other drugs given concurrently, patients should take Fenofibrate Tablets at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colchicine</p><p>Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrate coadministered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine.</p><p>Driving and using machines</p><p>Fenofibrate Tablets 48mg and 145mg is not likely to affect you being able to drive, use tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is one tablet each day. The tablet can be taken with or without food.</p><p>If you take more Fenofibrate Tablets 48mg and 145mg than you should</p><p>If you take too many tablets by mistake, contact your doctor immediately. Fenofibrate Tablets 48mg and 145mg will not work faster or better if you take it more than once a day.</p><p>If you forget to take Fenofibrate Tablets 48mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of the side effects are temporary with continued treatment or disappeared when treatment is stopped.</p><p>Clinical Trials Experience</p><p>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p><p>Adverse events reported by 2% or more of patients treated with fenofibrate (and greater than placebo) during the double-blind, placebo-controlled trials, regardless of causality, are listed in Table 1 below. Adverse events led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo. Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double blind trials.</p><p>&nbsp;</p><p>Table 1. Adverse Reactions Reported by 2% or More of Patients Treated with Fenofibrate And Greater than Placebo during the Double-Blind, Placebo-Controlled Trials</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>BODY SYSTEM</strong></p><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>Fenofibrate</strong></p><p><strong>* (N=439)</strong></p></td><td style="vertical-align:top"><p><strong>Placeb</strong></p><p><strong>o</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>BODY AS A WHOLE</strong></p></td></tr><tr><td style="vertical-align:top"><p>Abdominal Pain</p></td><td style="vertical-align:top"><p>4.6%</p></td><td style="vertical-align:top"><p>4.4%</p></td></tr><tr><td style="vertical-align:top"><p>Back Pain</p></td><td style="vertical-align:top"><p>3.4%</p></td><td style="vertical-align:top"><p>2.5%</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>3.2%</p></td><td style="vertical-align:top"><p>2.7%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>DIGESTIVE</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>2.3%</p></td><td style="vertical-align:top"><p>1.9%</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>2.1%</p></td><td style="vertical-align:top"><p>1.4%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>METABOLIC AND NUTRITIONAL DISORDERS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Abnormal Liver Function Tests</p></td><td style="vertical-align:top"><p>7.5%**</p></td><td style="vertical-align:top"><p>1.4%</p></td></tr><tr><td style="vertical-align:top"><p>Increased ALT</p></td><td style="vertical-align:top"><p>3.0%</p></td><td style="vertical-align:top"><p>1.6%</p></td></tr><tr><td style="vertical-align:top"><p>Increased CPK</p></td><td style="vertical-align:top"><p>3.0%</p></td><td style="vertical-align:top"><p>1.4%</p></td></tr><tr><td style="vertical-align:top"><p>Increased AST</p></td><td style="vertical-align:top"><p>3.4%**</p></td><td style="vertical-align:top"><p>0.5%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>RESPIRATORY</strong></p></td></tr><tr><td style="vertical-align:top"><p>Respiratory Disorder</p></td><td style="vertical-align:top"><p>6.2%</p></td><td style="vertical-align:top"><p>5.5%</p></td></tr><tr><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top"><p>2.3%</p></td><td style="vertical-align:top"><p>1.1%</p></td></tr><tr><td style="vertical-align:top"><p>* Dosage equivalent to 145 mg Fenofibrate Tablets.</p><p>** Significantly different from Placebo.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Urticaria was seen in 1.1% vs. 0%, and rash in 1.4% vs. 0.8% of fenofibrate and placebo patients Respectively in controlled trials</p><p>Postmarketing Experience</p><p>The following adverse reactions have been identified during post approval use of fenofibrate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: myalgia, rhabdomyolysis, pancreatitis, acute renal failure, muscle spasm, hepatitis, cirrhosis, anemia, arthralgia, decreases in hemoglobin, decreases in haematocrit, white blood cell decreases, asthenia, severely depressed HDL-cholesterol levels, and interstitial lung disease. Photosensitivity reactions have occurred days to months after initiation; in some of these cases, patients reported a prior photosensitivity reaction to ketoprofen</p><p>Reporting of side effect</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&bull;&nbsp; Saudi Arabia<em>:</em></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o&nbsp; Toll free phone: 8002490000</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: www.sfda.gov.sa/npc</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:88.2pt;margin-top:14.85pt;width:382.5pt;height:124.75pt;
  z-index:-251658240;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:66.95pt;
     margin-bottom:0in;margin-left:5.15pt;margin-bottom:.0001pt;line-height:
     150%'>The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax:
     +966-11-205-7662<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:5.15pt;line-height:13.75pt;
     mso-line-height-rule:exactly'>o Call NPC at +966-11-2038222, Exts:
     2317-2356-2353-2354-2334-2340.<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.8pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>Toll free phone:<span
     style='letter-spacing:-.15pt'> </span>8002490000<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.9pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>E-mail:<span
     style='letter-spacing:-.1pt'> </span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:blue;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.9pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-9.1pt;
     mso-list:l0 level1 lfo1;tab-stops:14.25pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>Website:<span
     style='letter-spacing:-.15pt'> </span><a href="http://www.sfda.gov.sa/npc"><span
     style='color:blue;text-decoration:none;text-underline:none'>www.sfda.gov.sa/npc</span></a><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong><em>o Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Fenofibrate Tablets contains:</strong></p><p>The active substance is Fenofibrate.</p><p>Each film coated tablet contains Fenofibrate Ph.Eur 48 mg.</p><p>The other ingredients are: Hypromellose, Lactose monohydrate, Sucrose Cellulose, microcrystalline Sodium lauryl sulphate, Croscarmellose sodium, and Magnesium stearate Purified water.</p><p>&nbsp;</p><p>Film Coating Composition: Poly vinyl alcohol Titanium Dioxide, Talc, Lecithin (Soy), Xanthan gum</p><p>Each film coated tablet contains Fenofibrate Ph.Eur 145mg.</p><p>The other ingredients are: Hypromellose, Lactose monohydrate, Sucrose Cellulose, microcrystalline Sodium lauryl sulphate, Croscarmellose sodium, and Magnesium stearate Purified water.</p><p>Film Coating Composition: Poly vinyl alcohol Titanium Dioxide, Talc, Lecithin (Soy), Xanthan gum, D&amp; C Yellow # Aluminium lake, FD&amp; C Yellow #6 Sunset Yellow FCF Aluminium lake, FD&amp; C Blue #2 Indigo Carmine Aluminium lake .</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Fenofibrate Tablets looks like? Fenofibrate Tablets 48mg
Yellow, oval, biconvex film coated tablets, debossed with 'J' on one side and '137' on other side.
Fenofibrate Tablets 145mg
White to off white oval, biconvex film coated tablets, debossed with 'J' on one side and '136' on other side.
How supplied:
Fenofibrate Tablets are supplied in blister pack. 
Fenofibrate Tablets 48mg- 3X10’s Alu-Alu blister
 Fenofibrate Tablets 145mg - 3X10’s Alu-Alu blister
 Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia</p><p>Tel: +966 11 477 221</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تنتمي أقراص ليبوفريت إلى مجموعة من الأدوية تسمى فيبرات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط كوليسترول الدم الأولي أو خلل شحوم الدم المختلط</p><p dir="RTL">يتم وصف أقراص ليبوفريت كعلاج مساعد للنظام الغذائي لتخفيض نسبة الكوليسترول البروتين الدهني المنخفض الكثافة (LDL-C) والكوليسترول الكلي (Total- C) والدهون الثلاثية والبروتينات البروتينية الدهنية (Apo B)، وزيادة الكوليسترول الدهني عالي الكثافة -C) في المرضى البالغين المصابين بفرط كوليسترول الدم الأولي أو خلل الدهون في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الدهون الثلاثية الشديدة</p><p dir="RTL">يتم وصف أقراص ليبوفريت كعلاج مساعد للنظام الغذائي لعلاج المرضى البالغين المصابين بارتفاع نسبة الدهون الثلاثية الشديدة. إن تحسين التحكم في نسبة السكر في الدم لدى مرضى السكري الذين يظهرون صيام الكيلومكرونات في الدم الصائم عادةً ما يتجنب الحاجة إلى التدخل الدوائي. مستويات مرتفعة بشكل ملحوظ من الدهون الثلاثية في الدم (على سبيل المثال&gt; 2000 ملغ / ديسيلتر) قد تزيد من خطر الإصابة بالتهاب البنكرياس. لم يكن تأثير علاج فينوفايبرات على تقليل هذا الخطر درس بشكل كاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيود المهمة على استخدام فينوفايبرات بجرعة تعادل 145 ملغم من ليبوفريت أقراص لم تُظهر أنها تقلل من معدلات المرض ووفيات أمراض الشريان التاجي في تجربة عشوائية ذات شواهد كبيرة لمرضى داء السكري من النوع 2.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وتستخدم هذه الأدوية لخفض مستويات الدهون في الدم، على سبيل المثال المعروفة باسم الدهون الثلاثية.</p><p dir="RTL">يستخدم ليبوفريت بالتعاون مع نظام غذائي يعمل على خفض الدهون وغيرها من العلاجات غير الدوائية مثل ممارسة الرياضة والحد من الوزن لخفض مستويات الدهون في الدم.</p><p dir="RTL">ويمكن استخدام ليبوفريت عندما تكون المنتجات الطبية الأخرى [ستاتين] غير مناسبة، من أجل الحد من خطر حدوث مشاكل في القلب بين الأشخاص ذوي الخطورة العالية وأولئك الذين يعانون من ارتفاع &ldquo;نسبة الكوليسترول الضار&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب على المرضى الالتزام بنظام غذائي مناسب لخفض الدهون قبل تناول ليبوفريت أقراص، ويجب أن يستمر هذا النظام الغذائي أثناء العلاج بتناول ليبوفريت أقراص. ويمكن تناول ليبوفريت أقراص دون اعتبار للوجبات.</p><p dir="RTL">العلاج الأولي لاضطرابات الدهون في الدم هو علاج غذائي محدد لنوع البروتين الدهني الغير طبيعي. قد يكون وزن الجسم الزائد والإفراط في تناول الكحوليات من العوامل التي تؤدي إلى ارتفاع الدهون الثلاثية وينبغي معالجة ذلك قبل أي علاج دوائي. يمكن أن يكون إجراءً التمرينات البدنية مساعدًا مهمًا. الأمراض التي تسهم في فرط دهون الدم، مثل قصور الغدة الدرقية أو داء السكري، يجب التحقق منها وعلاجها بشكل مناسب. في بعض الأحيان يرتبط العلاج بالأستروجين ومدرّات البول الثيازيدية وحاصرات بيتا بالارتفاعات الهائلة لنسبة الدهون الثلاثية في البلازما، خاصةً في الأشخاص الذين يعانون من فرط الدهون الثلاثية العائلي. في مثل هذه الحالات، قد يؤدي إيقاف العامل المسبب لارتفاع الدهون الثلاثية في الدم إلى تجنب الحاجة إلى علاج دوائي محدد لفرط الدهون الثلاثية.</p><p dir="RTL">يجب مراقبة مستويات الدهون بشكل دوري مع الأخذ في الاعتبار لتقليل جرعة ليبوفريت أقراص إذا انخفضت مستويات الدهون بشكل كبير عن النطاق المستهدف.</p><p dir="RTL">يجب سحب العلاج في المرضى الذين ليس لديهم استجابة كافية بعد شهرين من العلاج بتناول الجرعة القصوى الموصي بها والمقدرة بتركيز 145 ملغم مرة واحدة يوميًا.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الحالات المرضية وحالات الوفيات الناتجة عن أمراض القلب التاجية</strong></p><p dir="RTL">لم يتم إثبات تأثير تناول ليبوفريت أقراص على نسبة الحالات المرضية وحالات الوفيات الناتجة عن أمراض القلب التاجية وكذلك حالات الوفيات الناتجة عن أمراض القلب الغير مرتبط بالمشاكل الوعائية.</p><p dir="RTL">كانت تجربة العمل للتحكم في مخاطر الإصابة بأمراض القلب والأوعية الدموية في مرضى السكري مع ارتفاع نسبة الدهون (ACCORD Lipid) عبارة عن دراسة عشوائية خاضعة بمرجعية الدواء الوهمي أجريت على 5518 مريضًا من المصابين بداء السكري من النوع 2 ويتناولون علاج من مجموعة ستاتين حيث يتناولون فينوفايبرات. وكان متوسط ​​مدة المتابعة 4.7 سنوات. أظهرت النتائج أن العلاج بتناول فينوفايبرات بالإضافة إلى مركب الستاتين نسب منخفضة بنسبة 8٪ في المخاطر الأولية في الآثار الجانبية القلبية الوعائية الضارة (MACE)، وتتمثل في احتشاء عضلة القلب غير المميت والسكتة الدماغية غير القاتلة ووفيات أمراض القلب والأوعية الدموية (نسبة الخطر [HR] 0.92، 95 ٪ CI 0.79-1.08) (p = 0.32) بالمقارنة مع الستاتين مستقلا. في تحليل مجموعة فرعية بين الجنسين، كانت نسبة الخطر لحالات MACE في الرجال الذين يتلقون العلاج المركب مقابل الستاتين مستقلا 0.82 (95 ٪ CI 0.69-0.99)، ونسبة الخطر لحالات MACE في النساء اللائي يتلقين العلاج المركب مقابل الستاتين مستقلا كانت 1.38 (95 ٪ CI 0،98-1،94) (التفاعل p = 0.01).</p><p dir="RTL">أهمية الدراسات السريرية لهذه النتيجة الفرعية غير واضحة. كانت دراسة تدرس آثار العلاج بتناول فايبرات على المدى الطويل على أمراض القلب والشرايين (FIELD) عبارة عن دراسة عشوائية بمرجعية الدواء الوهمي استمرت 5 سنوات وشملت 9795 مريضاً مصابين بداء السكري من النوع 2 عولجوا بتناول فينوفايبرات. أظهر فينوفايبرات انخفاضًا نسبيًا غير مهم بنسبة 11٪ في النتيجة الأولية لأحداث أمراض القلب التاجية (نسبة الخطورة [HR] 0.89، 95٪ CI 0.75-1.05، p = 0.16) وتقليل كبير بنسبة 11٪ في النتيجة الثانوية الإجمالية أحداث أمراض القلب والأوعية الدموية (HR 0.89 [0.80-0.99]، p = 0.04). كان هناك 11 ٪ غير مهم (HR 1.11 [0.95، 1.29]، p = 0.18) و19 ٪ (HR 1.19 [0.90، 1.57]، p = 0.22) زيادة في الوفيات الكلية وأمراض القلب التاجية، على التوالي، مع تناول فينوفايبرات بالمقارنة مع الدواء الوهمي.</p><p dir="RTL">بسبب التشابهات الكيميائية والصيدلانية والسريرية بين ليبوفريت أقراص وكلوفيبيرات وجيمفيبروزيل، فإن النتائج السلبية في 4 دراسات سريرية بمرجعية الدواء الوهمي كبيرة وقد تنطبق أيضًا على ليبوفريت أقراص.</p><p dir="RTL">في مشروع عقاقير الشريان التاجي، وهي دراسة كبيرة عن احتشاء عضلة القلب في المرضى الذين عولجوا لمدة 5 سنوات بتناول كلوفيبرات، لم يكن هناك فرق في الوفيات التي لوحظت بين مجموعة كلوفيبرات ومجموعة الدواء الوهمي. ومع ذلك، كان هناك اختلاف في معدل تكون الحصوات الصفراوية والتهاب المرارة التي تتطلب جراحة بين المجموعتين (3.0 ٪ مقابل 1.8 ٪). في دراسة أجرتها منظمة الصحة العالمية (WHO)، عولج 5000 شخص بدون مرض الشريان التاجي المعروف بالدواء الوهمي وكلوفيبرات لمدة 5 سنوات وتم متابعتهم لمدة عام إضافي. كان هناك دلالة إحصائية على وفيات بمعدلات أعلى حسب العمر الزائد في المجموعة كلوفيبرات مقارنة مع مجموعة الدواء الوهمي (5.70 ٪ مقابل 3.96 ٪، P = &lt;0.01). كان معدل الوفيات الزائدة بسبب زيادة بنسبة 33 ٪ في الأسباب غير القلبية الوعائية، بما في ذلك الأورام الخبيثة، ومضاعفات استئصال المرارة، والتهاب البنكرياس. ويبدو أن هذا يؤكد ارتفاع خطر الإصابة بمرض المرارة في المرضى الذين عولجوا بتناول كلوفيبرات الذين تمت دراستهم في مشروع عقاقير الشريان التاجي. كانت دراسة هلسنكي للقلب دراسة كبيرة (n = 4081) على الرجال في منتصف العمر دون تاريخ مرضي بالشريان التاجي. تم تناول الدواء الوهمي وجيمفيبروزيل لمدة 5 سنوات، مع تمديد مفتوح للمتابعة لمدة 3.5 سنوات بعد ذلك. وكان إجمالي الوفيات أعلى عدديا في المجموعة العشوائية جيمفيبروزيل لكنه لم يحقق دلالة إحصائية (P = 0.19، فاصل الثقة 95 ٪ للمخاطر النسبية G: P = .91-1.64). على الرغم من أن حالات الوفاة بالسرطان تتجه نحو الأعلى في مجموعة جيمفيبروزيل (p = 0.11)، فقد تم تشخيص السرطانات (باستثناء سرطان الخلايا القاعدية) بمعدلات متساويةٍ في مجموعتي الدراسة. نظرًا للحجم المحدود للدراسة، لم يكن الخطر النسبي للوفاة من أي سبب مختلفًا عن ذلك الذي ظهر في بيانات المتابعة لمدة 9 سنوات من دراسة منظمة الصحة العالمية (RR = 1.29).</p><p dir="RTL">عنصر الوقاية الثانوية في دراسة هلسنكي للقلب على الرجال المسجلين في منتصف العمر المستبعدين من دراسة الوقاية الأولية بسبب مرض القلب التاجي المعروف أو المشتبه به. تم تناول الدواء الوهمي وجيمفيبروزيل لمدة 5 سنوات. على الرغم من أن الوفيات القلبية تتجه نحو الأعلى في مجموعة جيمفيبروزيل، إلا أن هذا لم يكن ذو دلالة إحصائية (نسبة الخطر 2.2، فاصل الثقة 95٪: 0.94-5.05). لم يكن معدل جراحة المرارة ذات دلالة إحصائية بين مجموعات الدراسة، ولكنها كانت أعلى في المجموعة جيمفيبروزيل، (1.9 ٪ مقابل 0.3 ٪، P = 0.07).</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>العضلات الهيكلية</strong></p><p dir="RTL">تزيد الفايبرات من خطر الإصابة بالاعتلال العضلي وترتبط بحالات انحلال الربيدات. يبدو أن خطر التسمم العضلي الخطير يزداد عند المرضى المسنين وفي مرضى السكري أو القصور الكلوي أو قصور الغدة الدرقية.</p><p dir="RTL">يجب النظر إلى الاعتلال العضلي لدى أي مريض مصاب بألم عضلي منتشر، أو لين عضلي أو ضعف، و / أو ارتفاعات ملحوظة لمستويات فسفوكيناز الكرياتين (CPK). يجب أن ينصح المرضى بالإبلاغ الفوري عن آلام العضلات، أو لين أو الضعف غير المبررة، خاصةً إذا كان مصحوبًا بتوعك أو حمى. يجب تقييم مستويات CPK في المرضى الذين يبلغون عن هذه الأعراض، ويجب إيقاف علاج ليبوفريت أقراص إذا حدث ارتفاع مستويات من CPK بشكل ملحوظ أو كان يشتبه أو يتم تشخيص التهاب عضلي / عضلي.</p><p dir="RTL">تشير البيانات المستقاة من الدراسات القائمة على الملاحظة إلى أن خطر انحلال الربيدات يزداد عندما يتم استخدام الفايبرات، وخاصة الجيمبروزيل، مع مثبط إنزيم HMG-CoA (الستاتين). يجب تجنب المزيج ما لم يكن من المحتمل أن تفوق فائدة إجراء المزيد من التعديلات في مستويات الدهون على زيادة خطر هذه التركيبة الدوائية. تم الإبلاغ عن حالات اعتلال عضلي، بما في ذلك انحلال الربيدات، باستخدام فينوفايبرات يشترك فيها مع كولشيسين، ويجب توخي الحذر عند وصف فينوفايبرات مع الكولشيسين.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>وظائف الكبد</strong></p><p dir="RTL">ارتبط تناول فينوفايبرات بجرعات تعادل 96 ملغم إلى 145 ملغم ليبوفريت أقراص يوميًا بزيادة في إنزيمات ناقلات الأمين في الدم [AST (SGOT) أو ALT (SGPT)]. في تحليل مُجمَّع لـ 10 تجارب تم المقارنة فيها بالدواء الوهمي، ارتفع الحد الأعلى الطبيعي إلى 3 أضعاف في 5.3٪ من المرضى الذين يتناولون فينوفايبرات مقابل 1.1٪ من المرضى الذين عولجوا بالدواء الوهمي.</p><p dir="RTL">عندما تم متابعة نسبة إنزيمات ناقلات الأمين في الدم إما بعد توقف العلاج أو أثناء العلاج المستمر، لوحظت عادة العودة إلى الحدود الطبيعية. يبدو أن نسبة حدوث الزيادات في إنزيمات ناقلات الأمين في الدم المرتبطة بعلاج فينوفايبرات مرتبطة بالجرعة. في دراسة على مدى جرعة لمدة 8 أسابيع، كانت نسبة حدوث ارتفاعات ALT أو AST إلى ثلاثة أضعاف الحد الأعلى الطبيعي 13٪ في المرضى الذين يتناولون جرعات تعادل 96 ملغم إلى 145 ملغم ليبوفريت أقراص يوميًا وكان 0٪ في أولئك الذين يتناولون جرعات تعادل 48 ملغم أو أقل من ليبوفريت أقراص في اليوم، أو الدواء الوهمي. تم الإبلاغ عن التهاب الكبد الخلوي، التهاب الكبد المزمن النشط المرتبط بالعلاج بتناول الفينوفايبرات بعد التعرض لعدة أسابيع إلى عدة سنوات. في حالات نادرة للغاية، تم الإبلاغ عن تليف الكبد بالاشتراك مع التهاب الكبد النشط المزمن. يجب إجراء متابعة والرصد الدوري المنتظم لوظائف الكبد، بما في ذلك ALT (SGPT) في الدم أثناء مدة العلاج مع ليبوفريت أقراص، وتوقف المعالجة إذا استمرت مستويات الإنزيم فوق ثلاثة أضعاف الحد الطبيعي.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الكرياتينين في الدم</strong></p><p dir="RTL">تم الإبلاغ عن الارتفاعات في نسبة الكرياتينين في الدم في المرضى الذين يتناولون فينوفايبرات. هذه الارتفاعات تميل إلى العودة إلى المعدلات الطبيعية بعد توقف فينوفايبرات. الأهمية السريرية لهذه الملاحظات غير معروفة. يجب مراقبة وظائف الكلى في المرضى الذين يعانون من القصور الكلوي مع تناول ليبوفريت أقراص. كما يجب مراعاة ومراقبة الكلى للمرضى الذين يتناولون ليبوفريت أقراص ولديهم خطر الإصابة بقصور كلوي مثل كبار السن ومرضى السكري.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الحصاة الصفراوية</strong></p><p dir="RTL">فينوفايبرات، مثل كلوفيبرات وجمفبروزيل، قد تزيد إفراز الكولسترول في الصفراء، مما يؤدي إلى تكون حصوات صفراوية. إذا كان يشتبه في تكون حصوات صفراوية، فيجب فحص المرارة. ويجب وقف العلاج بتناول ليبوفريت أقراص إذا تم الكشف عن حصى في المرارة.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مضادات التخثر (الكومارين)</strong></p><p dir="RTL">يجب توخي الحذر عند استخدام مضادات التخثر من نوع الكومارين بالتزامن مع ليبوفريت أقراص بسبب تقوية تأثيرات مضادات التخثر من النوع الكومارين في إطالة فترة البروثرومبين / النسبة الطبيعية الدولية (PT / INR). لمنع حدوث مضاعفات النزيف، يوصى بمراقبة متكررة لنسبة PT / INR وتعديل جرعة مضاد التخثر حتى تستقر نسبة PT / INR.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التهاب البنكرياس</strong></p><p dir="RTL">تم الإبلاغ عن حالات التهاب البنكرياس في المرضى الذين يتناولون فينوفايبرات وجيمفيبروزيل وكلوفيبرات. قد يمثل هذا الحدث فشلًا في الفعالية لدى مرضى الذين يعانون من فرط الدهون الثلاثية الشديدة، أو تأثير دوائي مباشر، أو ظاهرة ثانوية تتوسط من خلال حصاة القناة الصفراوية أو تكوين الترسيبات مع انسداد القناة الصفراوية الشائع.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التغييرات الدموية</strong></p><p dir="RTL">لوحظت انخفاضات خفيفة إلى معتدلة في الهيموجلوبين، الهيماتوكريت، وانخفاض خلايا الدم البيضاء في المرضى بعد بدء العلاج بتناول فينوفايبرات. ومع ذلك، فإن هذه المستويات تستقر خلال الاستخدام طويلة الأجل. تم الإبلاغ عن نقص الصفيحات وندرة المحببات في الأفراد الذين عولجوا باستخدام الفينوفايبرات. يوصى بمراقبة دورية لتعداد خلايا الدم الحمراء والبيضاء خلال الأشهر الـ 12 الأولى من تناول ليبوفريت أقراص.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تفاعلات فرط الحساسية</strong></p><p dir="RTL">فرط الحساسية الحاد</p><p dir="RTL">تم الإبلاغ عن الحساسية المفرطة وذمة وعائية بعد تسويق فينوفايبرات. في بعض الحالات، كانت ردود الفعل تهدد الحياة وتتطلب العلاج في حالات الطوارئ. إذا ظهر على المريض علامات أو أعراض رد فعل فرط الحساسية الحاد، وتقديم المشورة لهم للحصول على عناية طبية فورية وتوقف فينوفايبرات.</p><p dir="RTL">فرط الحساسية المتأخر</p><p dir="RTL">تم الإبلاغ عن التفاعلات الجانبية الضارة والحادة (SCAR)، بما في ذلك متلازمة ستيفنز-جونسون، وتنخر البشرة عن طريق الجلد السام، وردود الفعل الدوائية مع فرط الحمضات والأعراض الجهازية (DRESS)، في مرحلة ما بعد التسويق، تحدث بعد أيام إلى أسابيع من بدء العلاج بتناول فينوفايبرات. ارتبطت حالات DRESS بتفاعلات جلدية (مثل طفح جلدي أو التهاب جلدي تقشري) ومجموعة من فرط الحمضات، حمى، أعراض جانبية لأعضاء أخرى (كلوي، كبدي، أو تنفسي). التوقف عن فينوفايبرات وعلاج المرضى بشكل مناسب إذا كان يشتبه في SCAR.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مرض انسداد الشرايين</strong></p><p dir="RTL">في التجربة الميدانية، لوحظ وجود انسداد رئوي (PE) وتجلط الأوردة العميقة (DVT) بمعدلات أعلى مع تناول فينوفايبرات - من المجموعة التي عولجت بالعلاج الوهمي. من بين 9795 مريض مسجلين في FIELD، كان هناك 4900 مريض الذين تناولوا مجموعة العلاج الوهمي و4995 مريض في مجموعة الذين تناولوا فينوفايبرات. ل DVT، كان هناك 48 حدثا (1 ٪) في المجموعة الثانية و67 (1 ٪) في مجموعة فينوفايبرات (p = 0.074)؛ وبالنسبة لـ PE، كان هناك 32 (0.7٪) من الأحداث في مجموعة الدواء الوهمي و53 (1٪) في مجموعة فينوفايبرات (p = 0.022). في مشروع عقاقير الشريان التاجي، شهدت نسبة أعلى من مجموعة كوليفايبرات انسدادًا رئويًا قاتلًا أو غير مميت أو مشتبه به من انسداد رئوي أو التهاب الوريد الخثاري مقارنةً بالمجموعة الثانية (5.2٪ مقابل 3.3٪ في خمس سنوات ؛ P &lt;0.01).</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">يجب عدم استخدام ليبوفريت أقراص 48 ملغم و145 ملغم في الأطفال. لا توجد بيانات توضح فعالية أو سلامة ليبوفريت أقراص في الأطفال</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>أدوية أخرى مع ليبوفريت أقراص:</strong><strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التخثر (الكومارين)</p><p dir="RTL">قد لوحظ تعزيز آثار مضادات التخثر من نوع الكومارين مع إطالة PT / INR. يجب توخي الحذر عند إعطاء مضادات التخثر الكومارين بالتزامن مع ليبوفريت أقراص. يجب تقليل جرعة مضادات التخثر للحفاظ على PT / INR في المستوى المطلوب لمنع مضاعفات النزيف. يُنصح بتحديد اختبارات PT / INR المتكررة إلى أن يتقرر بالتأكيد أن PT / INR قد استقرت [انظر التحذيرات والاحتياطات (5.6)].</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المثبطات المناعية</p><p dir="RTL">المثبطات المناعية مثل السيكلوسبورين والتكروليم يمكن أن تنتج سمية كلوية مع انخفاض في تصفية الكرياتينين وارتفاع في الكرياتينين في الدم، ولأن إفراز الكلى هو طريق الأساسي للتخلص من عقاقير الفايبرات بما في ذلك ليبوفريتومات، هناك خطر من أن التفاعل قد يؤدي إلى تدهور وظائف الكلى. ينبغي النظر بعناية في فوائد ومخاطر استخدام (ليبوفريت أقراص) مع مثبطات المناعة وغيرها من العوامل التي يحتمل أن تكون سامة للأمعاء، ويجب مراقبة أقل جرعة فعالة ومراقبة وظائف الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; راتنجات ربط (محتجزات) حمض الصفراء</p><p dir="RTL">نظرًا لأن راتنجات حمض الصفراء قد تربط الأدوية الأخرى التي تعطى بشكل متزامن، يجب على المرضى تناول ليبوفريت أقراص قبل ساعة أو 4 إلى 6 ساعات على الأقل من تناول راتنج ربط حمض الصفراء لتجنب إعاقة امتصاصه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكوليشسين</p><p dir="RTL">تم الإبلاغ عن حالات اعتلال عضلي، بما في ذلك انحلال الربيدات، باستخدام فينوفايبرات مع الكوليشسين، ويجب توخي الحذر عند وصف فينوفايبرات مع كوليشسين.</p><p dir="RTL"><strong>القيادة واستخدام الآلات: </strong></p><p dir="RTL">من غير المحتمل أن يؤثر تناول. ليبوفريت أقراص 48 ملغم و145ملغم لن يؤثر على قدرتك على القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائمًا تناول هذا الدواء كما وصف الطبيب لك، استشر طبيبك أو الصيدلي إن لم تكن متأكداً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصي بها هي قرص واحد كل يوم. يمكن تناول القرص مع أو بدون الطعام.</p><p dir="RTL"><strong>تناول جرعة زائدة من ليبوفريت أقراص:</strong></p><p dir="RTL">إذا تناولت ليبوفريت أقراص أكثر مما ينبغي عن طريق الخطأ، اتصل بطبيبك على الفور. ليبوفريت أقراص 48 ملغم و145ملغم لن تعمل بشكل أسرع أو أفضل إذا كنت تتناول جرعة أكثر من مرة واحدة في اليوم.</p><p dir="RTL"><strong>نسيان تناول ليبوفريت أقراص:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة لتعويض الجرعة منسية.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حصول الجميع عليها. بعض الآثار الجانبية مؤقتة مع استمرار العلاج أو تختفي عند توقف العلاج.</p><p dir="RTL"><strong>تقارير التجارب السريرية</strong></p><p dir="RTL">نظرًا لأن الدراسات السريرية تُجرى في ظل ظروف متباينة وعلى نطاق واسع، فإن معدلات التفاعل السلبي التي لوحظت في الدراسات السريرية للدواء لا يمكن مقارنتها مباشرة بالمعدلات في الدراسات السريرية لعقار آخر وقد لا تعكس المعدلات التي لوحظت في الاستخدام الطبيعي.</p><p dir="RTL">يتم سرد التأثيرات السلبية التي أبلغ عنها 2 ٪ أو أكثر من المرضى والذين عولجوا باستخدام الفينوفيبرات (وأكبر من الدواء الوهمي) <strong>أثناء تجارب المقارنة المزدوجة لتأثير الدواء الفعلي والدواء الوهمي،</strong> بغض النظر عن السببية، في الجدول 1 أدناه. أدت التأثيرات السلبية إلى وقف العلاج في 5.0 ٪ من المرضى الذين عولجوا باستخدام الفينوفايبرات وفي 3.0 ٪ والذين عولجوا بالدواء الوهمي. كانت الزيادات في نتائج اختبارات وظائف الكبد هي التأثيرات الأكثر شيوعًا، مما تسبب في توقف علاج الفينوفايبريت في 1.6٪ من المرضى في التجارب المزدوجة العمياء.</p><p dir="RTL"><strong>الجدول 1. ردود الفعل السلبية التي أبلغ عنها 2 ٪ أو أكثر من المرضى الذين عولجوا باستخدام الفينوفايبرات وأكبر من الدواء الوهمي أثناء تجارب المقارنة المزدوجة لتأثير الدواء الفعلي والدواء الوهمي</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>أعضاء الجسم</strong></p><p dir="RTL"><strong>التأثير الجانبي</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>فينوفايبريت</strong></p><p dir="RTL"><strong>* (N=439)</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الدواء</strong><strong>&nbsp;الوهمي</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p dir="RTL"><strong>الجسم كاملا</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">آلام في البطن</p></td><td style="vertical-align:top"><p dir="RTL">4.6%</p></td><td style="vertical-align:top"><p dir="RTL">4.4%</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">آلام الظهر</p></td><td style="vertical-align:top"><p dir="RTL">3.4%</p></td><td style="vertical-align:top"><p dir="RTL">2.5%</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الصداع</p></td><td style="vertical-align:top"><p dir="RTL">3.2%</p></td><td style="vertical-align:top"><p dir="RTL">2.7%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p dir="RTL"><strong>الجهاز الهضمي</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الغثيان</p></td><td style="vertical-align:top"><p dir="RTL">2.3%</p></td><td style="vertical-align:top"><p dir="RTL">1.9%</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الإمساك</p></td><td style="vertical-align:top"><p dir="RTL">2.1%</p></td><td style="vertical-align:top"><p dir="RTL">1.4%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p dir="RTL"><strong>اضطرابات التمثيل الغذائي والتغذوي</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">نتائج اختبارات وظائف الكبد غير الطبيعية</p></td><td style="vertical-align:top"><p dir="RTL">7.5%**</p></td><td style="vertical-align:top"><p dir="RTL">1.4%</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">زيادة ALT</p></td><td style="vertical-align:top"><p dir="RTL">3.0%</p></td><td style="vertical-align:top"><p dir="RTL">1.6%</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">زيادة CPK</p></td><td style="vertical-align:top"><p dir="RTL">3.0%</p></td><td style="vertical-align:top"><p dir="RTL">1.4%</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">زيادة AST</p></td><td style="vertical-align:top"><p dir="RTL">3.4%**</p></td><td style="vertical-align:top"><p dir="RTL">0.5%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p dir="RTL"><strong>الجهاز التنفسي</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطراب الجهاز التنفسي</p></td><td style="vertical-align:top"><p dir="RTL">6.2%</p></td><td style="vertical-align:top"><p dir="RTL">5.5%</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب الأنف</p></td><td style="vertical-align:top"><p dir="RTL">2.3%</p></td><td style="vertical-align:top"><p dir="RTL">1.1%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p dir="RTL">* الجرعة تعادل 145 ملغ ليبوفريت أقراص.</p><p dir="RTL">** مختلفة بشكل كبير عن الدواء الوهمي.</p></td></tr></tbody></table><p dir="RTL">لوحظت حالات الأرتكاريا بنسبة 1.1٪ مقابل 0٪، والطفح الجلدي بنسبة 1.4٪ مقابل 0.8٪ في مرضى الذين يتناولون الفينوفايبرات والدواء الوهمي على التوالي في التجارب المرجعية</p><p dir="RTL"><strong>تقارير ما بعد التسويق</strong></p><p dir="RTL">تم رصد ردود الفعل السلبية التالية أثناء استخدام فينوفايبرات بعد اعتماد تسويقه. نظرًا لأن هذه التفاعلات يتم الإبلاغ عنها طوعًا من مجموعة سكانية ذات حجم غير مؤكد، فمن غير الممكن دائمًا تقدير معدلاتها بشكل موثوق أو تأسيس علاقة سببية بالتعرض للأدوية: ألم عضلي، انحلال الربيدات، التهاب البنكرياس، فشل كلوي حاد، تشنج عضلي، التهاب الكبد، فقر الدم، ألم مفصلي، انخفاض في نسبة الهيموجلوبين، انخفاض في الهيماتوكريت، نقص خلايا الدم البيضاء، الوهن، انخفاض مستويات الكوليسترول الجيد، وأمراض الرئة الخلالية. حدثت تفاعلات الحساسية للضوء بعد أيام إلى أشهر من البدء؛ في بعض هذه الحالات، أبلغ المرضى عن تفاعلات حساسية سابق للكيتوبروفين</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة، يرجى إبلاغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:558px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222 ، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc .drug@sfda .gov .sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www .sfda .gov .sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
   height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp;&nbsp; يرجى الاتصال بالسلطة الصحية المختصة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ عند درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في عبوته الأصلية لحمايته من الرطوبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم موكسيفلوكس أقراص بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أوعن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;ما تحويه علبة ليبوفريت أقراص: </strong></p><p dir="RTL"><strong>ليبوفريت أقراص 48 ملغم</strong></p><p dir="RTL">المادة الفعالة هي فينوفايبرات</p><p dir="RTL">يحتوي كل قرص مغلف بطبقة رقيقة على 48 ملغم فينوفايبرات المتوافق مع دستور الأدوية الأوروبي.</p><p dir="RTL"><strong>الصواغات الأخرى:</strong> هيدروكسي بروبيل ميثيل سيللوز، لاكتوز أحادي الهيدرات، السكروز، السليولوز دقيق التبلور الصوديوم لوريل سلفات، كروس كارميلوز الصوديوم، وستيرات الماغنيسيوم والمياه النقية.</p><p dir="RTL"><strong>الصواغات الأخرى لطبقة الكسوة هي</strong>: كحول البولي فينيل ثاني أكسيد التيتانيوم، التلك، الليسيثين (الصويا)، صمغ الزانثان.</p><p dir="RTL"><strong>ليبوفريت أقراص 145 ملغم</strong></p><p dir="RTL">المادة الفعالة هي فينوفايبرات</p><p dir="RTL">يحتوي كل قرص مغلف بطبقة رقيقة على 145 ملغم فينوفايبرات المتوافق مع دستور الأدوية الأوروبي.</p><p dir="RTL"><strong>الصواغات الأخرى:</strong> هيدروكسي بروبيل ميثيل سيللوز، لاكتوز أحادي الهيدرات، السكروز، السليولوز دقيق التبلور الصوديوم لوريل سلفات، كروس كارميلوز الصوديوم، وستيرات الماغنيسيوم والمياه النقية.</p><p dir="RTL"><strong>الصواغات الأخرى لطبقة الكسوة هي</strong>: كحول البولي فينيل ثاني أكسيد التيتانيوم، التلك، الليسيثين (الصويا)، صمغ الزانثان. بالإضافة إلى صبغات: D&amp; C Yellow # Aluminium lake, FD&amp; C Yellow #6 Sunset Yellow FCF Aluminium lake, FD&amp; C Blue #2 Indigo Carmine Aluminium lake.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ليبوفريت أقراص 48 ملغم</strong></p><p dir="RTL">أقراص صفراء بيضاوية الشكل محدبة الوجهين، والأقراص مغلفة بطبقة رقيقة ومدموغة بحرف &quot;J&quot; من جانب ورقم &quot;137&quot; على الجانب الآخر.</p><p dir="RTL"><strong>ليبوفريت أقراص 145 ملغم</strong></p><p dir="RTL">أقراص بيضاوية الشكل محدبة الوجهين ذات اللون الأبيض إلى الأبيض القاتم، والأقراص مغلفة بطبقة رقيقة ومدموغة بحرف &quot;J&quot; من جانب ورقم &quot;136&quot; على الجانب الآخر.</p><p dir="RTL"><strong>توافر </strong><strong>ليبوفريت أقراص</strong><strong>:</strong></p><p dir="RTL">يتم توفير ليبوفريت أقراص في عبوات حاوية.</p><p dir="RTL">يتوافر ليبوفريت أقراص 48 ملغم في عبوات حاوية تحتوي على&nbsp; 3X10&nbsp; شرائط مصنوعة من Alu-Alu</p><p dir="RTL">يتوافر ليبوفريت أقراص 145 ملغم في عبوات حاوية تحتوي على&nbsp; 3X10&nbsp; شرائط مصنوعة من Alu-Alu</p><p dir="RTL">قد لا تتوافر كافة العبوات في السوق</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong></p><p dir="RTL">شارع الجامعة &ndash; الملز &ndash; الرياض 11441</p><p dir="RTL">المملكة العربية السعودية.</p><p dir="RTL">تليفون: + 966 114772215</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fenofibrate Tablets 145mg 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fenofibrate Tablets 145mg  
Each film coated tablet contains Fenofibrate Ph.Eur 145 mg.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fenofibrate Tablets 145mg 
White to off-white, oval, biconvex film coated tablets, debossed with 'J' on one side and '136' on other side. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.1.1.1&nbsp; </strong><strong>Primary Hypercholesterolemia or Mixed Dyslipidemia </strong></p><p>Fenofibrate Tablets is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.</p><p><strong>4.1.1.2&nbsp; </strong><strong>Severe Hypertriglyceridemia </strong></p><p>Fenofibrate Tablets is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.</p><p>Markedly elevated levels of serum triglycerides (e.g. &gt; 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied</p><p><strong>4.1.1.3&nbsp; </strong><strong>Important Limitations of Use </strong></p><p>Fenofibrate at a dose equivalent to 145 mg of Fenofibrate Tablets was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.1.1&nbsp; </strong><strong>Posology and method of administration </strong></p><p>Patients should be placed on an appropriate lipid-lowering diet before receiving Fenofibrate Tablets, and should continue this diet during treatment with Fenofibrate Tablets. Fenofibrate Tablets can be given without regard to meals.</p><p>The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides,</p><p>Especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. Lipid levels should be monitored periodically and consideration should be given to reducing the dosage of Fenofibrate Tablets if lipid levels fall significantly below the targeted range.</p><p>Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of 145 mg once daily 2.2 Primary Hypercholesterolemia or Mixed Dyslipidemia The initial dose of Fenofibrate Tablets is 145 mg once daily.</p><p><strong>4.2.1 Severe Hypertriglyceridemia </strong></p><p>The initial dose is 48 to 145 mg per day. Dosage should be individualized according to patient Response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals. The maximum dose is 145 mg once daily.</p><p><strong>4.2.2 Impaired Renal Function </strong></p><p>Treatment with Fenofibrate Tablets should be initiated at a dose of 48 mg per day in patients having mild to moderately impaired renal function, and increased only after evaluation of the effects on renal function and lipid levels at this dose. The use of Fenofibrate Tablets should be avoided in patients with severe renal impairment.</p><p>&nbsp;<strong>4.2.3 Geriatric Patients </strong></p><p>Dose selection for the elderly should be made on the basis of renal function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fenofibrate Tablets is contraindicated in: 
•	Patients with severe renal impairment, including those receiving dialysis  
•	Patients with active liver disease, including those with primary biliary cirrhosis and 
Unexplained persistent liver function abnormalities  
•	Patients with pre-existing gallbladder disease  
•	nursing mothers  
•	Patients with known hypersensitivity to fenofibrate or fenofibric acid  

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effect of Fenofibrate Tablets on coronary heart disease morbidity and mortality and noncardiovascular mortality has not been established.</p><p>The Action to Control Cardiovascular Risk in Diabetes Lipid (ACCORD Lipid) trial was a Randomized placebo-controlled study of 5518 patients with type 2 diabetes mellitus on background statin therapy treated with fenofibrate. The mean duration of follow-up was 4.7 years. Fenofibrate plus statin combination therapy showed a non-significant 8% relative risk reduction in the primary outcome of major adverse cardiovascular events (MACE), a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular disease death (hazard ratio [HR] 0.92, 95% CI 0.79-1.08) (p=0.32) as compared to statin monotherapy. In a gender subgroup analysis, the hazard ratio for MACE in men receiving combination therapy versus statin monotherapy was 0.82 (95% CI 0.69-0.99), and the hazard ratio for MACE in women</p><p>Receiving combination therapy versus statin monotherapy was 1.38 (95% CI 0.98-1.94) (interaction p=0.01). The clinical significance of this subgroup finding is unclear. The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study was a 5-year randomized, placebo-controlled study of 9795 patients with type 2 diabetes mellitus treated with fenofibrate. Fenofibrate demonstrated a non-significant 11% relative reduction in the primary outcome of coronary heart disease events (hazard ratio [HR] 0.89, 95% CI 0.75-1.05, p=0.16) and a significant 11% reduction in the secondary outcome of total cardiovascular disease events (HR 0.89 [0.80-0.99], p=0.04). There was a non-significant 11% (HR 1.11 [0.95, 1.29], p=0.18) and 19% (HR 1.19 [0.90, 1.57], p=0.22) increase in total and coronary heart disease mortality, respectively, with fenofibrate as compared to placebo.</p><p>Because of chemical, pharmacological, and clinical similarities between Fenofibrate Tablets (fenofibrate tablets), clofibrate, and gemfibrozil, the adverse findings in 4 large randomized, placebo controlled Clinical studies with these other fibrate drugs may also apply to Fenofibrate Tablets.</p><p>In the Coronary Drug Project, a large study of post myocardial infarction of patients treated for 5 Years with clofibrate, there was no difference in mortality seen between the clofibrate group and the placebo group. There was however, a difference in the rate of Cholelithiasis and cholecystitis</p><p>Requiring surgery between the two groups (3.0% vs. 1.8%) In a study conducted by the World Health Organization (WHO), 5000 subjects without known coronary artery disease were treated with placebo or clofibrate for 5 years and followed for an additional one year. There was a statistically significant, higher age &minus; adjusted all-cause mortality in the clofibrate group compared with the placebo group (5.70% vs. 3.96%, p = &lt; 0.01). Excess mortality was due to a 33% increase in non-cardiovascular causes, including malignancy, post-cholecystectomy complications, and pancreatitis. This appeared to confirm the higher risk of gallbladder disease seen in clofibrate-treated patients studied in the Coronary Drug Project.</p><p>The Helsinki Heart Study was a large (n=4081) study of middle-aged men without a history of coronary artery disease. Subjects received either placebo or gemfibrozil for 5 years, with a 3.5 year open extension afterward. Total mortality was numerically higher in the gemfibrozil randomization group but did not achieve statistical significance (p = 0.19, 95% confidence interval for relative risk G:P = .91-1.64). Although cancer deaths trended higher in the gemfibrozil group (p = 0.11), cancers (excluding basal cell carcinoma) were diagnosed with equal frequency in both study groups. Due to the limited size of the study, the relative risk of death from any cause was not shown to be different than that seen in the 9 year follow-up data from World Health Organization study (RR=1.29).</p><p>A secondary prevention component of the Helsinki Heart Study enrolled middle-aged men excluded from the primary prevention study because of known or suspected coronary heart disease. Subjects received gemfibrozil or placebo for 5 years. Although cardiac deaths trended higher in the gemfibrozil group, this was not statistically significant (hazard ratio 2.2, 95%confidence interval: 0.94-5.05). The rate of gallbladder surgery was not statistically significant between study groups, but did trend higher in the gemfibrozil group, (1.9% vs. 0.3%, p = 0.07).</p><p>&bull; <strong>Skeletal Muscle </strong></p><p>Fibrates increase the risk for myopathy and have been associated with rhabdomyolysis. The risk for serious muscle toxicity appears to be increased in elderly patients and in patients with diabetes, renal insufficiency, or hypothyroidism.</p><p>Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevations of creatine phosphokinase (CPK) levels.</p><p>Patients should be advised to report promptly unexplained muscle pain, tenderness or weakness, Particularly if accompanied by malaise or fever. CPK levels should be assessed in patients reporting these symptoms, and Fenofibrate Tablets therapy should be discontinued if markedly elevated CPK levels occur or myopathy/myositis is suspected or diagnosed.</p><p>Data from observational studies indicate that the risk for rhabdomyolysis is increased when</p><p>Fibrates, in particular gemfibrozil, are co-administered with an HMG-CoA reductase inhibitor (statin). The combination should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates coadministered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Liver Function </strong></p><p>Fenofibrate at doses equivalent to 96 mg to 145 mg Fenofibrate Tablets per day has been associated with increases in serum transaminases [AST (SGOT) or ALT (SGPT)]. In a pooled analysis of 10 placebo-controlled trials, increases to &gt; 3 times the upper limit of normal occurred in 5.3% of patients taking fenofibrate versus 1.1% of patients treated with placebo.</p><p>When transaminase determinations were followed either after discontinuation of treatment or during continued treatment, a return to normal limits was usually observed. The incidence of increases in transaminases related to fenofibrate therapy appear to be dose related. In an 8-week dose-ranging study, the incidence of ALT or AST elevations to at least three times the upper limit of normal was 13% in patients receiving dosages equivalent to 96 mg to 145 mg Fenofibrate Tablets per day and was 0% in those receiving dosages equivalent to 48 mg or less Fenofibrate Tablets per day, or placebo. Hepatocellular, chronic active and cholestatic hepatitis associated with fenofibrate therapy have been reported after exposures of weeks to several years. In extremely rare cases, cirrhosis has been reported in association with chronic active hepatitis. Baseline and regular periodic monitoring of liver function, including serum ALT (SGPT) should be performed for the duration of therapy with Fenofibrate Tablets, and therapy discontinued if enzyme levels persist above three times the normal limit.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Serum Creatinine </strong></p><p>Elevations in serum creatinine have been reported in patients on fenofibrate. These elevations tend to return to baseline following discontinuation of fenofibrate. The clinical significance of these observations is unknown. Monitor renal function in patients with renal impairment taking Fenofibrate Tablets. Renal monitoring should also be considered for patients taking Fenofibrate Tablets at risk for renal insufficiency such as the elderly and patients with diabetes.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cholelithiasis </strong></p><p>Fenofibrate, like clofibrate and gemfibrozil, may increase cholesterol excretion into the bile, Leading to Cholelithiasis. If cholelithiasis is suspected, gallbladder studies are indicated.</p><p>Fenofibrate Tablets therapy should be discontinued if gallstones are found.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Coumarin Anticoagulants </strong></p><p>Caution should be exercised when coumarin anticoagulants are given in conjunction with Fenofibrate Tablets because of the potentiation of coumarin-type anticoagulant effects in prolonging the Prothrombin Time/International Normalized Ratio (PT/INR). To prevent bleeding complications, frequent monitoring of PT/INR and dose adjustment of the anticoagulant are recommended until PT/INR has stabilized.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pancreatitis </strong></p><p>Pancreatitis has been reported in patients taking fenofibrate, gemfibrozil, and clofibrate. This Occurrence may represent a failure of efficacy in patients with severe hypertriglyceridemia, a direct drug effect, or a secondary phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hematologic Changes </strong></p><p>Mild to moderate hemoglobin, hematocrit, and white blood cell decreases have been observed in patients following initiation of fenofibrate therapy. However, these levels stabilize during long term administration. Thrombocytopenia and agranulocytosis have been reported in individuals treated with fenofibrate. Periodic monitoring of red and white blood cell counts are recommended during the first 12 months of Fenofibrate Tablets administration.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hypersensitivity Reactions </strong></p><p>Acute Hypersensitivity</p><p>Anaphylaxis and angioedema have been reported postmarketing with fenofibrate. In some cases, reactions were life-threatening and required emergency treatment. If a patient develops signs or symptoms of an acute hypersensitivity reaction, advise them to seek immediate medical attention and discontinue fenofibrate.</p><p>Delayed Hypersensitivity</p><p>Severe cutaneous adverse drug reactions (SCAR), including Stevens-Johnson syndrome, toxic epidermal necrolysis, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported postmarketing, occurring days to weeks after initiation of fenofibrate. The cases of DRESS were associated with cutaneous reactions (such as rash or exfoliative dermatitis) and a combination of eosinophilia, fever, systemic organ involvement (renal, hepatic, or respiratory). Discontinue fenofibrate and treat patients appropriately if SCAR is suspected</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Venothromboembolic Disease </strong></p><p>In the FIELD trial, pulmonary embolus (PE) and deep vein thrombosis (DVT) were observed at higher rates in the fenofibrate- than the placebo-treated group. Of 9,795 patients enrolled in FIELD, there were 4,900 in the placebo group and 4,895 in the fenofibrate group. For DVT, there were 48 events (1%) in the placebo group and 67 (1%) in the fenofibrate group (p = 0.074); and for PE, there were 32 (0.7%) events in the placebo group and 53 (1%) in the fenofibrate group (p = 0.022).</p><p>In the Coronary Drug Project, a higher proportion of the clofibrate group experienced definite or Suspected fatal or nonfatal pulmonary embolism or thrombophlebitis than the placebo group (5.2% vs. 3.3% at five years; p &lt; 0.01).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Paradoxical Decreases in HDL Cholesterol Levels </strong></p><p>There have been postmarketing and clinical trial reports of severe decreases in HDL cholesterol levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibrate therapy. The decrease in HDL-C is mirrored by a decrease in apolipoprotein A1. This decrease has been reported to occur within 2 weeks to years after initiation of fibrate therapy. The HDL-C levels remain depressed until fibrate therapy has been withdrawn; the response to withdrawal of fibrate therapy is rapid and sustained. The clinical significance of this decrease in HDL-C is unknown. It is recommended that HDL-C levels be checked within the first few months after initiation of fibrate therapy. If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline, and fibrate therapy should not be re-initiated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Coumarin Anticoagulants </strong></p><p>Potentiation of coumarin-type anticoagulant effects has been observed with prolongation of the PT/INR.</p><p>Caution should be exercised when coumarin anticoagulants are given in conjunction with Fenofibrate tablets. The dosage of the anticoagulants should be reduced to maintain the PT/INR at the desired level to prevent bleeding complications. Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized</p><p>Immunosuppressant&rsquo;s</p><p>Immunosuppressant&rsquo;s such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including Fenofibrate Tablets, there is a risk that an interaction will lead to deterioration of renal function. The benefits and risks of using Fenofibrate Tablets (fenofibrate tablets) with immunosuppressant&rsquo;s and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed and renal function monitored.</p><p><strong>Bile Acid Binding Resins </strong></p><p>Since bile acid binding resins may bind other drugs given concurrently, patients should take Fenofibrate Tablets at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption.</p><p><strong>Colchicine </strong></p><p>Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates coadministered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy </strong></p><p>Risk Summary</p><p>Limited available data with fenofibrate use in pregnant women are insufficient to determine a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no evidence of embryo-fetal toxicity was observed with oral administration of fenofibrate in rats and rabbits during organogenesis at doses less than or equivalent to the maximum recommended clinical dose of 145 mg daily, based on body surface area (mg/m2). Adverse reproductive outcomes occurred at higher doses in the presence of maternal toxicity (see Data). Fenofibrate Tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data</p><p><em>Animal Data </em></p><p>In pregnant rats given oral dietary doses of 14, 127, and 361 mg/kg/day from gestation day 6-15 during the period of organogenesis, no adverse developmental findings were observed at 14 mg/kg/day (less than the clinical exposure at the maximum recommended human dose [MRHD] of 300 mg fenofibrate daily, equivalent to 145 mg Fenofibrate Tablets daily, based on body surface area Comparisons). Increased fetal skeletal malformations were observed at maternally toxic doses (361 mg/kg/day, corresponding to 12 times the clinical exposure at the MRHD) that significantly suppressed maternal body weight gain In pregnant rabbits given oral gavage doses of 15, 150, and 300 mg/kg/day from gestation day 6- 18 during the period of organogenesis and allowed to deliver, no adverse developmental findings were observed at 15 mg/kg/day (a dose that approximates the clinical exposure at the MRHD, based on body surface area comparisons). Aborted litters were observed at maternally toxic doses (&ge; 150 mg/kg/day, corresponding to &ge; 10 times the clinical exposure at the MRHD) that suppressed maternal body weight gain.</p><p>In pregnant rats given oral dietary doses of 15, 75, and 300 mg/kg/day from gestation day 15 through lactation day 21 (weaning), no adverse developmental effects were observed at 15 mg/kg/day (less than the clinical exposure at the MRHD, based on body surface area comparisons), despite maternal toxicity (decreased weight gain). Post-implantation loss was observed at &ge; 75 mg/kg/day (&ge; 2 times the clinical exposure at the MRHD) in the presence of maternal toxicity (decreased weight gain). Decreased pup survival was noted at 300 mg/kg/day (10 times the clinical exposure at the MRHD), which was associated with decreased maternal body weight gain/maternal neglect.</p><p><strong>Lactation </strong></p><p>Risk Summary</p><p>There is no available information on the presence of fenofibrate in human milk, effects of the drug on the breastfed infant, or the effects on milk production. Fenofibrate is present in the milk of rats, and is therefore likely to be present in human milk. Because of the potential for serious adverse reactions in breastfed infants, such as disruption of infant lipid metabolism, women should not breastfeed during treatment with Fenofibrate Tablets and for 5 days after the final dose.&nbsp;</p><p><strong>Pediatric Use </strong></p><p>Safety and effectiveness have not been established in pediatric patients.</p><p><strong>Geriatric Use </strong></p><p>Fenofibric acid is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Fenofibric acid exposure is not influenced by age. Since elderly patients have a higher incidence of renal impairment, dose selection for the elderly should be made on the basis of renal function.&nbsp; Elderly patients with normal renal function should require no dose modifications. Consider monitoring renal function in elderly patients taking Fenofibrate Tablets.</p><p><strong>Renal Impairment </strong></p><p>The use of Fenofibrate Tablets should be avoided in patients who have severe renal impairment&nbsp;&nbsp; Dose reduction is required in patients with mild to moderate renal Impairment. Monitoring renal function in patients with renal impairment is recommended.</p><p><strong>Hepatic Impairment </strong></p><p>The use of Fenofibrate Tablets has not been evaluated in subjects with hepatic impairment&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fenofibrate Tablets 48mg and 145mg has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Clinical Trials Experience</p><p>Because clinical studies are conducted under widely varying conditions, adverse reaction rates Observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Adverse events reported by 2% or more of patients treated with fenofibrate (and greater than placebo) during the double-blind, placebo-controlled trials, regardless of causality, are listed in Table 1 below.</p><p>Adverse events led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo. Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double blind trials.</p><p><strong>Table 1. Adverse Reactions Reported by 2% or More of Patients Treated with Fenofibrate and Greater than Placebo During the Double-Blind, Placebo-Controlled Trials </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:599px"><tbody><tr><td><p><strong>BODY SYSTEM</strong></p></td><td style="vertical-align:top"><p><strong>Fenofibrate* (N=439)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo (N=365)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p><p><strong>BODY AS A WHOLE</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>Abdominal Pain</p></td><td style="vertical-align:bottom"><p>4.6%</p></td><td style="vertical-align:bottom"><p>4.4%</p></td></tr><tr><td style="vertical-align:bottom"><p>Back Pain</p></td><td style="vertical-align:bottom"><p>3.4%</p></td><td style="vertical-align:bottom"><p>2.5%</p></td></tr><tr><td style="vertical-align:bottom"><p>Headache</p></td><td style="vertical-align:bottom"><p>3.2%</p></td><td style="vertical-align:bottom"><p>2.7%</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>DIGESTIVE</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>Nausea</p></td><td style="vertical-align:bottom"><p>2.3%</p></td><td style="vertical-align:bottom"><p>1.9%</p></td></tr><tr><td style="vertical-align:bottom"><p>Constipation</p></td><td style="vertical-align:bottom"><p>2.1%</p></td><td style="vertical-align:bottom"><p>1.4%</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>METABOLIC AND NUTRITIONAL DISORDERS</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>Abnormal Liver Function Tests</p></td><td style="vertical-align:bottom"><p>7.5%**</p></td><td style="vertical-align:bottom"><p>1.4%</p></td></tr><tr><td style="vertical-align:bottom"><p>Increased ALT</p></td><td style="vertical-align:bottom"><p>3.0%</p></td><td style="vertical-align:bottom"><p>1.6%</p></td></tr><tr><td style="vertical-align:bottom"><p>Increased CPK</p></td><td style="vertical-align:bottom"><p>3.0%</p></td><td style="vertical-align:bottom"><p>1.4%</p></td></tr><tr><td style="vertical-align:bottom"><p>Increased AST</p></td><td style="vertical-align:bottom"><p>3.4%**</p></td><td style="vertical-align:bottom"><p>0.5%</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>RESPIRATORY</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>Respiratory Disorder</p></td><td style="vertical-align:bottom"><p>6.2%</p></td><td style="vertical-align:bottom"><p>5.5%</p></td></tr><tr><td style="vertical-align:bottom"><p>Rhinitis</p></td><td style="vertical-align:bottom"><p>2.3%</p></td><td style="vertical-align:bottom"><p>1.1%</p></td></tr><tr><td><p>* Dosage equivalent to 145 mg TRICOR.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>** Significantly different from Placebo.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>Urticaria was seen in 1.1% vs. 0%, and rash in 1.4% vs. 0.8% of fenofibrate and placebo patients respectively in controlled trials.</p><p><strong>Postmarketing Experience</strong></p><p>The following adverse reactions have been identified during post approval use of fenofibrate.</p><p>Because these reactions are reported voluntarily from a population of uncertain size, it is not Always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: myalgia, rhabdomyolysis, pancreatitis, acute renal failure, muscle spasm, hepatitis, cirrhosis, anemia, arthralgia, decreases in hemoglobin, decreases in hematocrit, white blood cell decreases, asthenia, severely depressed HDL-cholesterol levels, and interstitial lung disease.</p><p>Photosensitivity reactions have occurred days to months after initiation; in some of these cases, Patients reported a prior photosensitivity reaction to ketoprofen.</p><p><strong><u>Reporting of suspected adverse reactions&nbsp;</u></strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em>Saudi Arabia<em>: </em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:510px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong>o Other GCC States: </strong>|<br />Please contact the relevant competent authority.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment for overdose with Fenofibrate Tablets. General supportive care of the patient is indicated, including monitoring of vital signs and observation of clinical status, should an overdose occur. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage; usual precautions should be observed to maintain the airway. Because fenofibric acid is highly bound to plasma proteins, hemodialysis should not be considered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Mechanism of Action </strong></p><p>The active moiety of Fenofibrate Tablets is fenofibric acid. The pharmacological effects of fenofibric acid in both animals and humans have been extensively studied through oral administration of fenofibrate.</p><p>The lipid-modifying effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor &alpha; (PPAR&alpha;). Through this mechanism, fenofibrate increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity).</p><p>The resulting decrease in TG produces an alteration in the size and composition of LDL from small, dense particles (which are thought to be atherogenic due to their susceptibility to oxidation), to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. Activation of PPAR&alpha; also induces an increase in the synthesis of apolipoproteins A-I, A-II and HDL-cholesterol. Fenofibrate also reduces serum uric acid levels in hyperuricemia and normal individuals by Increasing the urinary excretion of uric acid.</p><p><strong>5.1 Pharmacodynamic properties </strong></p><p>A variety of clinical studies have demonstrated that elevated levels of total-C, LDL-C, and apo B, an LDL membrane complex, are associated with human atherosclerosis. Similarly, decreased levels of HDL-C and its transport complex, apolipoprotein A (apo AI and apo AII) are associated with the development of atherosclerosis. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C, LDL-C, and TG, and inversely with the level of HDL-C. The independent effect of raising HDL-C or lowering triglycerides (TG) on the risk of cardiovascular morbidity and mortality has not been determined. Fenofibric acid, the active metabolite of fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apolipoproteins apoAI and apoAII&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Plasma concentrations of fenofibric acid after administration of three 48 mg or one 145 mg tablets are equivalent under fed conditions to one 200 mg micronized fenofibrate capsule. Fenofibrate is a pro-drug of the active chemical moiety fenofibric acid. Fenofibrate is converted by ester hydrolysis in the body to fenofibric acid which is the active constituent measurable in the circulation.</p><p>Absorption</p><p>The absolute bioavailability of fenofibrate cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection. However, fenofibrate is well absorbed from the Gastrointestinal tract. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate, and 25% was excreted in the feces. Peak plasma levels of fenofibric acid occur within 6 to 8 hours after administration.&nbsp;</p><p>Exposure to fenofibric acid in plasma, as measured by Cmax and AUC, is not significantly different when a single 145 mg dose of fenofibrate is administered under fasting or non fasting conditions.</p><p>Distribution</p><p>Upon multiple dosing of fenofibrate, fenofibric acid steady state is achieved within 9 days. Plasma concentrations of fenofibric acid at steady state are approximately double of those following a single dose. Serum protein binding was approximately 99% in normal and hyperlipidaemia subjects.</p><p>Metabolism</p><p>Following oral administration, fenofibrate is rapidly hydrolyzed by esterases to the active metabolite, fenofibric acid; no unchanged fenofibrate is detected in plasma. Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. A small amount of fenofibric acid is reduced at the carbonyl moiety to a benzhydrol metabolite which is, in turn, conjugated with glucuronic acid and excreted in urine.</p><p><em>In vivo </em>metabolism data indicate that neither fenofibrate nor fenofibric acid undergo oxidative Metabolism (e.g., cytochrome P450) to a significant extent.</p><p>Elimination</p><p>After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide. After administration of radiolabelled fenofibrate, approximately 60% of the dose appeared in the urine and 25% was excreted in the feces.</p><p>Fenofibric acid is eliminated with a half-life of 20 hours, allowing once daily dosing.</p><p>Special Populations</p><p>Geriatrics</p><p>In elderly volunteers 77 to 87 years of age, the oral clearance of fenofibric acid following a single oral dose of fenofibrate was 1.2 L/h, which compares to 1.1 L/h in young adults. This indicates that a similar dosage regimen can be used in elderly with normal renal function, without increasing accumulation of the drug or metabolites.&nbsp;</p><p>Pediatrics</p><p>The pharmacokinetics of Fenofibrate Tablets has not been studied in pediatric populations Gender No pharmacokinetic difference between males and females has been observed for fenofibrate.</p><p>Race</p><p>The influence of race on the pharmacokinetics of fenofibrate has not been studied, however fenofibrate is not metabolized by enzymes known for exhibiting inter-ethnic variability.</p><p>Renal Impairment</p><p>The pharmacokinetics of fenofibric acid was examined in patients with mild, moderate, and severe renal impairment. Patients with severe renal impairment (estimated glomerular filtration rate [eGFR] &lt; 30 mL/min/1.73m2) showed 2.7-fold increase in exposure for fenofibric acid and increased accumulation of fenofibric acid during chronic dosing compared to that of healthy subjects. Patients with mild to moderate renal impairment (eGFR 30-59 mL/min/1.73m2) had similar exposure but an increase in the half-life for fenofibric acid compared to that of healthy subjects. Based on these findings, the use of Fenofibrate Tablets should be avoided in patients who have</p><p>Severe renal impairment and dose reduction is required in patients having mild to moderate renal Impairment.</p><p>Hepatic Impairment</p><p>No pharmacokinetic studies have been conducted in patients with hepatic impairment.&nbsp;</p><p>&nbsp;Drug-drug Interactions</p><p><em>In vitro </em>studies using human liver microsomes indicate that fenofibrate and fenofibric acids are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2. They are weak inhibitors of CYP2C8, CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.</p><p>Table 2 describes the effects of co-administered drugs on fenofibric acid systemic exposure.</p><p>Table 3 describes the effects of co-administered fenofibrate or fenofibric acid on other drugs</p><p>Table 2. Effects of Co-Administered Drugs on Fenofibric Acid Systemic Exposure from<strong> </strong></p><p>Fenofibrate Administration Changes in Fenofibric Acid Exposure<strong> </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:609px"><tbody><tr><td style="vertical-align:top"><p>Co-</p><p>Administere d</p></td><td style="vertical-align:top"><p>Dosage Regimen of</p><p>Co-Administered</p><p>Drug</p></td><td style="vertical-align:top"><p>Dosage Regimen of Fenofibrate</p></td><td colspan="2" style="vertical-align:top"><p>Changes in</p><p>Fenofibric Acid</p><p>Exposure</p></td></tr><tr><td style="vertical-align:top"><p>Drug</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>AUC</p></td><td style="vertical-align:top"><p>Cmax</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Lipid-lowering agents</em></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Atorvastatin</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>20 mg once daily for 10 days</p></td><td style="vertical-align:top"><p>1 Fenofibrate 160 mg</p><p>&nbsp;</p><p>once daily for 10 days</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&darr;2%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&darr;4%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Pravastatin</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>40 mg as a single dose</p></td><td style="vertical-align:top"><p>2 Fenofibrate 3 x 67 mg as</p><p>a single dose</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&darr;1%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&darr;2%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Fluvastatin</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>40 mg as a single dose</p></td><td style="vertical-align:top"><p>1 Fenofibrate 160 mg as a single dose</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&darr;2%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&darr;10%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Anti-diabetic agents</em></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Glimepiride</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1 mg as a single dose</p></td><td style="vertical-align:top"><p>1</p><p>Fenofibrate 145 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; once</p><p>daily for 10 days</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&uarr;1%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&darr;1%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Metformin</p></td><td style="vertical-align:top"><p>850 mg three times</p><p>daily for 10 days</p></td><td style="vertical-align:top"><p>1</p><p>Fenofibrate &nbsp;&nbsp;&nbsp; 54 &nbsp;&nbsp;&nbsp; mg</p><p>three times daily for 10</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&darr;9%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&darr;6%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rosiglitazone</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8 mg once daily for 5 days</p></td><td style="vertical-align:top"><p>1</p><p>Fenofibrate 145 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; once</p><p>daily for 14 days</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&uarr;10%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&uarr;3%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>1</p><p>Fenofibrate Tablets (fenofibrate) oral tablet</p><p>2</p><p>Fenofibrate Tablets (fenofibrate) oral micronized capsule</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Table 3. Effects of Fenofibrate Co-Administration on Systemic Exposure of Other Drugs </em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:609px"><tbody><tr><td style="vertical-align:top"><p>Dosage &nbsp;&nbsp;&nbsp; Regimen</p><p>of Fenofibrate</p></td><td style="vertical-align:top"><p>Dosage</p><p>Co- Drug</p></td><td colspan="3" style="vertical-align:top"><p>Regimen &nbsp;&nbsp; of</p><p>Administered</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Change &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Co-</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administered &nbsp;&nbsp; Drug</p><p>Exposure</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Analyte</p></td><td style="vertical-align:top"><p>AUC</p></td><td style="vertical-align:top"><p>Cma</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Lipid-lowering agents</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>1</p><p>Fenofibrate 160 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; once</p><p>daily for 10 days</p></td><td colspan="2" style="vertical-align:top"><p>Atorvastatin, 20 daily for 10 days</p></td><td style="vertical-align:top"><p>mg</p></td><td style="vertical-align:top"><p>once</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Atorvastatin</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&darr;17%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;0%</p></td></tr><tr><td style="vertical-align:top"><p>2 Fenofibrate 3 x 67 mg as</p><p>a single dose</p></td><td colspan="3" style="vertical-align:top"><p>Pravastatin, 40 mg as a single dose</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Pravastatin</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&uarr;13%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&uarr;13%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>3&alpha;-Hydroxyl-</p><p>iso- pravastatin</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&uarr;26%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&uarr;29%</p></td></tr><tr><td style="vertical-align:top"><p>1 Fenofibrate 160 mg as a single dose</p></td><td colspan="3" style="vertical-align:top"><p>Fluvastatin, 40 mg as a single dose</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(+)-3R, 5S-</p><p>Fluvastatin</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&uarr;15%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&uarr;16%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Anti-diabetic agents</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>1</p><p>Fenofibrate 145 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; once</p><p>daily for 10 days</p></td><td colspan="3" style="vertical-align:top"><p>Glimepiride, 1 mg as a single dose</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Glimepiride</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&uarr;35%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&uarr;18%</p></td></tr><tr><td style="vertical-align:top"><p>1</p><p>Fenofibrate &nbsp;&nbsp;&nbsp; 54 &nbsp;&nbsp;&nbsp; mg</p><p>three times daily for 10</p></td><td colspan="4" style="vertical-align:top"><p>Metformin, &nbsp;&nbsp;&nbsp;&nbsp; 850 &nbsp;&nbsp;&nbsp;&nbsp; mg three times daily for 10</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Metformin</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&uarr;3%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&uarr;6%</p></td></tr><tr><td style="vertical-align:top"><p>1</p><p>Fenofibrate 145 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; once</p><p>daily for 14 days</p></td><td colspan="4" style="vertical-align:top"><p>Rosiglitazone, &nbsp;&nbsp;&nbsp; 8 &nbsp;&nbsp;&nbsp; mg</p><p>once daily for 5 days</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Rosiglitazone</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&uarr;6%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&darr;1%</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>3</p><p>Fenofibrate Tablets (fenofibrate) oral tablet</p><p>4</p><p>Fenofibrate Tablets (fenofibrate) oral micronized capsule</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogenesis and Mutagenesis and Impairment of Fertility </strong></p><p>Two dietary carcinogenicity studies have been conducted in rats with fenofibrate. In the first 24- month study, Wistar rats were dosed with fenofibrate at 10, 45, and 200 mg/kg/day, approximately 0.3, 1, and 6 times the maximum recommended human dose (MRHD) of 300 mg Fenofibrate daily, equivalent to 145 mg Fenofibrate Tablets daily, based on body surface area comparisons.</p><p>At a dose of 200 mg/kg/day (at 6 times the MRHD), the incidence of liver carcinomas was significantly increased in both sexes. A statistically significant increase in pancreatic carcinomas was observed in males at 1 and 6 times the MRHD; an increase in pancreatic adenomas and benign testicular interstitial cell tumour&rsquo;s was observed at 6 times the MRHD in males. In a second 24-month rat carcinogenicity study in a different strain of rats (Sprague-Dawley), doses of 10 and 60 mg/kg/day (0.3 and 2 times the MRHD) produced significant increases in the incidence of pancreatic acinar adenomas in both sexes and increases in testicular interstitial cell tumors in males at 2 times the MRHD.</p><p>A 117-week carcinogenicity study was conducted in rats comparing three drugs: fenofibrate 10 and 60 mg/kg/day (0.3 and 2 times the MRHD, based on body surface area comparisons), clofibrate (400 mg/kg/day; 2 times the human dose), and gemfibrozil (250 mg/kg/day; 2 times the human dose, based on mg/m2 surface area). Fenofibrate increased pancreatic acinar adenomas in both sexes. Clofibrate increased hepatocellular carcinoma and pancreatic acinar adenomas in males and hepatic neoplastic nodules in females. Gemfibrozil increased hepatic neoplastic nodules in males and females, while all three drugs increased testicular interstitial cell tumors in males.</p><p>In a 21-month study in CF-1 mice, fenofibrate 10, 45, and 200 mg/kg/day (approximately 0.2, 1, and 3 times the MRHD, based on body surface area comparisons) significantly increased the liver carcinomas in both sexes at 3 times the MRHD. In a second 18-month study at 10, 60, and 200 mg/kg/day, fenofibrate significantly increased the liver carcinomas in male mice and liver adenomas in female mice at 3 times the MRHD.</p><p>Electron microscopy studies have demonstrated peroxisomal proliferation following fenofibrate administration to the rat. An adequate study to test for peroxisome proliferation in humans has not been done, but changes in peroxisome morphology and numbers have been observed in humans after treatment with other members of the fibrate class when liver biopsies were compared before and after treatment in the same individual.</p><p>Fenofibrate has been demonstrated to be devoid of mutagenic potential in the following tests: Ames, mouse lymphoma, chromosomal aberration and unscheduled DNA synthesis in primary rat hepatocytes.</p><p>In fertility studies rats were given oral dietary doses of fenofibrate, males received 61 days prior to mating and females 15 days prior to mating through weaning which resulted in no adverse effect on fertility at doses up to 300 mg/kg/day (10 times the MRHD, based on body surface area Comparisons).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fenofibrate Tablets 145mg :&nbsp; </strong></p><p>&nbsp;The &nbsp;&nbsp;&nbsp; other &nbsp;&nbsp; ingredients &nbsp;&nbsp;&nbsp;&nbsp; are: &nbsp;&nbsp;&nbsp;&nbsp; Hypromellose, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactose &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; monohydrate, Sucrose &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cellulose,&nbsp;&nbsp; microcrystalline Sodium lauryl sulphate, Croscarmellose sodium, and Magnesium stearate Purified water.</p><p>Film Coating Composition: Poly vinyl alcohol Titanium Dioxide, Talc, Lecithin (Soy), Xanthan gum, D&amp; C Yellow # Aluminium lake, FD&amp; C Yellow #6 Sunset Yellow FCF Aluminium lake, FD&amp; C Blue #2 Indigo Carmine Aluminium lake .</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>3 X 10&rsquo;s Alu-Alu Blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Saudi Amarox Industrial Company 
Aljameah Street, Malaz quarter,  
Riyadh 11441, Saudi Arabia 
Tel: +966 11 477 2215 
Manufacture: 
Hetero Lab Limited Unit III, Hyderabad, India. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>